P Moosmann1, F Egli, R A Stahel, L Jost. 1. Department of Internal Medicine, Division of Medical Oncology, University Hospital of Zurich, Switzerland.
Abstract
BACKGROUND: The combination of paclitaxel and carboplatin is active in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, considerable toxicity develops with 3-weekly drug administration. Treatment on a weekly basis may allow for a higher dose intensity with less adverse effects. PATIENTS AND METHODS: Enrolled in this study were 31 patients with locally advanced, metastatic or relapsed SCCHN, most of them pretreated. They received weekly i.v. infusions of 80 mg/m(2) paclitaxel over 1 h combined with carboplatin at an area under the concentration time curve of 2 mg/ml/min over 30 min. RESULTS: The overall response rate was 52% with 1 complete response and 16 partial responses. Median progression-free survival was 5.4 months, median overall survival 12.8 months. Grade 3/4 hematologic adverse events occurred in 7 patients and grade 3 peripheral neuropathy in one. 10 patients required dose reduction or treatment delay due to neutropenia, thrombocytopenia or neuropathy. CONCLUSIONS: Weekly administration of paclitaxel and carboplatin appears to be safe and efficacious in patients with advanced, metastatic or recurrent SCCHN. Copyright 2003 S. Karger GmbH, Freiburg
BACKGROUND: The combination of paclitaxel and carboplatin is active in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, considerable toxicity develops with 3-weekly drug administration. Treatment on a weekly basis may allow for a higher dose intensity with less adverse effects. PATIENTS AND METHODS: Enrolled in this study were 31 patients with locally advanced, metastatic or relapsed SCCHN, most of them pretreated. They received weekly i.v. infusions of 80 mg/m(2) paclitaxel over 1 h combined with carboplatin at an area under the concentration time curve of 2 mg/ml/min over 30 min. RESULTS: The overall response rate was 52% with 1 complete response and 16 partial responses. Median progression-free survival was 5.4 months, median overall survival 12.8 months. Grade 3/4 hematologic adverse events occurred in 7 patients and grade 3 peripheral neuropathy in one. 10 patients required dose reduction or treatment delay due to neutropenia, thrombocytopenia or neuropathy. CONCLUSIONS: Weekly administration of paclitaxel and carboplatin appears to be safe and efficacious in patients with advanced, metastatic or recurrent SCCHN. Copyright 2003 S. Karger GmbH, Freiburg
Authors: L A Dunn; M G Fury; H Xiao; S S Baxi; E J Sherman; S Korte; C Pfister; S Haque; N Katabi; A L Ho; D G Pfister Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976
Authors: Hélène Carinato; Mickaël Burgy; Régine Ferry; Cathie Fischbach; Michal Kalish; Sébastien Guihard; Youssef Brahimi; Henri Flesch; Guy Bronner; Philippe Schultz; Véronique Frasie; Alicia Thiéry; Martin Demarchi; Thierry Petit; Alain C Jung; Pierre Wagner; Pierre Coliat; Christian Borel Journal: Front Oncol Date: 2021-10-27 Impact factor: 6.244
Authors: Adeline Pêtre; Cécile Dalban; Andy Karabajakian; Eve-Marie Neidhardt; Pierre Eric Roux; Marc Poupart; Sophie Deneuve; Philippe Zrounba; Jérome Fayette Journal: Oncotarget Date: 2018-04-24